TRI-SPRINTEC Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Tri-sprintec, and when can generic versions of Tri-sprintec launch?
Tri-sprintec is a drug marketed by Barr and is included in one NDA.
The generic ingredient in TRI-SPRINTEC is ethinyl estradiol; norgestimate. There are twenty-six drug master file entries for this compound. Twenty suppliers are listed for this compound. Additional details are available on the ethinyl estradiol; norgestimate profile page.
Summary for TRI-SPRINTEC
See drug prices for TRI-SPRINTEC
Recent Clinical Trials for TRI-SPRINTEC
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| University of Pennsylvania | Phase 1 |
| Society of Family Planning | Phase 1 |
| American Heart Association | Phase 4 |
Anatomical Therapeutic Chemical (ATC) Classes for TRI-SPRINTEC
US Patents and Regulatory Information for TRI-SPRINTEC
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Barr | TRI-SPRINTEC | ethinyl estradiol; norgestimate | TABLET;ORAL-28 | 075808-001 | Dec 29, 2003 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
